Sui, X., Zhang, R., Liu, S., Duan, T., Zhai, L., Zhang, M., et al. (2018) RSL3 Drives Ferroptosis through GPX4 Inactivation and ROS Production in Colorectal Cancer. Frontiers in Pharmacology, 9, Article No. 1371.
https://doi.org/10.3389/fphar.2018.01371

has been cited by the following article:

• TITLE: Unveiling the Hidden Power of Ferroptosis: A Promising Strategy for Treating Colorectal Cancer

  AUTHORS: Yalong Li, Jian Cheng, Chunling Li, Juan Miao, Jie Yang, Luyi Zhang, Chuyi Yang, Heng Zhang

  KEYWORDS: Colorectal Cancer, Ferroptosis, ROS, Pathogenesis, Diagnosis and Treatment

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.18 No.8, August 21, 2025

  ABSTRACT: With the emphasis on human health, colorectal cancer (CRC) has become the focus of public discussion. There are no effective treatments for CRC in clinical practice, and CRC patients tend to develop problems such as cancer recurrence in their prognosis. Therefore, new targets and strategies are urgently needed to treat CRC in clinical practice. Ferroptosis is a mode of cell death composed of iron ion accumulation and lipid peroxidation. It has been found that ferroptosis plays an important role in CRC. CRC cells often inhibit ferroptosis for survival, and therapeutic strategies aim to promote it. However, the specific molecular mechanism of ferroptosis in CRC has not been clearly investigated. In this manuscript, we present the molecular mechanisms of ferroptosis, the role of ferroptosis in CRC, and the possibility that targeting ferroptosis can diagnose and treat CRC early, providing new perspectives and directions for clinical treatment of CRC.